pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,491 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1464Fierce Biotech779BioSpace767BioPharma Dive554raps254onclive165fda recalls
therapy area
allOncology13092Rare Disease3386Immunology3069Cardiology2865Hematology2334Pulmonology2297Vaccines
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 1d agoDealPositive↗ source
  • U.S. loses measles elimination status as outbreaks claim first deaths in decades
    The Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…
    STAT · 19h agoNegative↗ source
← prev
page 2 of 140
next →
122
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Study finds malaria antibody L9LS reduces vaccine response in infants
    Researchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
    STAT · 19h agoNegative readoutNegative↗ source
  • Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher disease
    Sanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • Lawmakers push for stronger U.S. biotech support to stay ahead of China
    Members of the congressional Biotech Caucus told reporters that Washington must act quickly to boost the U.S. biotech sector and keep it ahead of China. They called for increased funding, streamli…
    STAT · 1d agoRegulatoryNeutral↗ source
  • Telehealth firms Hims & Hers and Noom launch prescription peptide programs after HHS rule change
    Telehealth companies Hims & Hers and Noom announced this week that they will begin prescribing peptide products to eligible patients, marking the first major consumer‑focused rollouts of such thera…
    STAT · 1d agoNeutral↗ source
  • Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patent
    Novartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…
    BioSpace · 1d agoNeutral↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 1d agoLayoffsNegative↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%
    Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
    BioSpace · 1d agoNegative readoutNegative↗ source
  • National Academies urges faster retractions and corrections to protect scientific record
    The National Academies of Sciences, Engineering, and Medicine released a report urging the scientific community to act more quickly when errors or data manipulation are identified in published rese…
    STAT · 1d agoPositive↗ source
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 1d agoRegulatoryNeutral↗ source
  • MAHA PAC spent more on its own D.C. steakhouse events than on a key ally’s House race before midterm losses
    The political arm of Make America Healthy Again (MAHA) directed millions of dollars to its own operations, including a high‑profile dinner in Washington, D.C., rather than funneling that money to c…
    STAT · 1d agoNegative↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • Sanders says expanded Medicare plan may still pass despite Trump’s potential veto
    Senator Bernie Sanders told reporters that he is not certain a Trump veto would block an expanded Medicare for All proposal, suggesting the legislation could still move forward. The proposal appea…
    STAT · 1d agoNeutral↗ source
  • Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese data
    Erasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…
    STAT · 1d agoNeutral↗ source
  • Study finds stopping statins in older adults may lead to worse outcomes despite non-inferior label
    A new trial called STREAM examined whether older adults without prior heart attacks or strokes could safely stop taking statins. The study was presented at the American Heart Association annual mee…
    STAT · 1d agoNegative readoutNeutral↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 1d agoDealNeutral↗ source
  • MAHA PAC’s spending favors allies over its own candidates, raising questions about strategy
    Recent filings reveal that the MAHA political action committee directed a sizable portion of its money toward allied groups, boosters and an affiliated nonprofit rather than directly funding its ow…
    STAT · 1d agoNegative↗ source
  • STAT+: Epic defends competitive practices; promises AI access to records
    In this edition of STAT Health Tech: EHR giant, Epic defends its competitive tactics, new data on AI and health care costs, and HLTH news.
    STAT · 1d ago↗ source
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    BioSpace · 1d ago↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 2d agoApprovalPositive↗ source
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 2d agoDealPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 2d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination, raising uncertainty for agency’s future
    The White House pulled its nomination of Heidi Overton for FDA commissioner, a move that surprised members of the Senate health committee. Overton’s removal leaves the agency without a permanent h…
    STAT · 1d agoRegulatoryNegative↗ source